Go or no go? Abbvie, Roche and Kala await key decisions - Vantage

Go or no go? Abbvie, Roche and Kala await key decisions  Vantage

One of the biggest drugs of the year, Abbvie's Jak inhibitor upadacitinib, could get the nod in August. A stamp saying "FDA approved". After a quiet couple of ...

Go or no go? Abbvie, Roche and Kala await key decisions - Vantage
続きを読む